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Background: Achieving target doses of angiotensin-converting-enzyme inhibitor/
angiotensin-receptor blockers (ACEi/ARB) and beta-blockers in heart failure with
reduced ejection fraction (HFrEF) is often underperformed. In BIOlogy Study to TAi-
lored Treatment in chronic heart failure (BIOSTAT-CHF) study, many patients were
not up-titrated for which no clear reason was reported. Therefore, we hypothesized
that perceived-risk profile might influence treatment optimization.
Methods: We studied 2100 patients with HFrEF (LVEF≤40%) to compare the clinical char-
acteristics and adverse events associatedwith treatmentup-titration (after a 3-month titration
protocol) between; a) patients not reaching target doses for unclear reason; b) patients not
reaching target doses due to symptoms and/or side effects; c) patients reaching target doses.
Results: For ACEi/ARB, (a), (b) and (c) was observed in 51.3%, 25.9% and 22.7% of
patients, respectively. For beta-blockers, (a), (b) and (c) was observed in 67.5%, 20.2%
and 12.3% of patients, respectively. By multinomial logistic regression analysis for
ACEi/ARB, patients in group (a) and (b) had lower blood pressure and poorer renal
function, and patients in group (a) were older and had lower ejection fraction. For
beta-blockers, patients in group (a) and (b) had more severe congestion and lower
heart rate. At 9 months, adverse events (i.e., hypotension, bradycardia, renal impair-
ment, and hyperkalemia) occurred similarly among the three groups.
Conclusions: Patients in whom clinicians did not give a reason why up-titration was
missed were older and had more co-morbidities. Patients in whom up-titration was
achieved did not have excess adverse events. However, from these observational
findings, the pattern of subsequent adverse events among patients in whom up-titra-
tion was missed cannot be determined.
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1 | INTRODUCTION
Up-titration of angiotensin converting enzyme inhibitor/angiotensin
receptor blockers (ACEi/ARB) and beta-blockers to target doses
reduces morbidity and mortality in heart failure with reduced ejection
fraction (HFrEF).1-7 Nonetheless, HF medications target doses are
often not achieved in clinical practice.8-11
A systems BIOlogy Study to TAilored Treatment in chronic heart
failure (BIOSTAT-CHF) included patients on suboptimal HFrEF ther-
apy in whom clinicians were encouraged (by protocol) to up-titrate to
target doses ACEi/ARBs and beta-blockers during first 3-months after
inclusion.12 In a previous BIOSTAT-CHF report, it was shown that
patients treated with less than 50% of recommended ACEi/ARB
and/or beta-blocker doses had a poorer prognosis.13
Physicians participating in BIOSTAT-CHF were specifically
instructed to record the reasons for not achieving the rec-
ommended target doses. Intriguingly, in most patients, no clear rea-
son was provided for not reaching target doses. In the present
study, we hypothesized that, in such cases, the 'unspecified rea-
sons' might be related to perceived but unreported higher patient-
risk profile, or to concern about the risk of expected patients' intol-
erance.14 Characterization and treatment-related adverse events
of these patients may help improve guideline-recommended treat-
ment optimization.
To this aim, we compared baseline characteristics and adverse
events associated with attempts of treatment up-titration among
patients not reaching target doses for unspecified reason, those not
reaching target doses due to symptoms and/or side effects, and those
reaching target doses.
2 | METHODS
2.1 | Patient population
The description of the BIOSTAT-CHF cohort has been previously
published.12,13 In brief, BIOSTAT-CHF was an investigator-driven
multi-center clinical study consisting of 2516 patients from 69 centers
in 11 European countries with symptoms of HF, which was confirmed
by left ventricular ejection fraction (LVEF) ≤40% and/or brain natri-
uretic peptide >400 pg/ml or N-terminal pro BNP (NT-proBNP)
>2000 pg/ml and treatment of furosemide. Patients were receiving
<50% of the guideline-recommended target doses of at least one of
ACEi/ARBs and beta-blockers at the time of inclusion (visit 1).
Patients underwent a 3-month up-titration period when the treating
physicians were encouraged to initiate or up-titrate ACEi/ARB and
beta-blockers to target doses.15 For the following 6 months, no fur-
ther medication changes were mandated unless clinically indicated,
and the 9-month visit (visit 2) was performed.
For this analysis, we included patients with a LVEF≤40% who sur-
vived at the end of first 3-month up-titration period as previously
published.13 Patients were considered successfully up-titrated when
patients achieved guideline-recommended target dose after the
3-months up-titration period. According to recorded reasons for not
reaching target doses in the case report form (CRF), patients were
divided into three groups as previously shown13: (a) those in whom
clinicians did not report a reason for not reaching target doses,
(b) those who did not reach target doses because they experienced
symptom, side effects or non-cardiac organ dysfunction, and (c) those
who reached target doses.
Ethics Board approval was obtained, and all participants signed
written informed consent prior to entry into the study.
2.2 | Adverse events associated with ACEi/ARB or
beta-blockers and high-risk subgroups
The incidence of adverse events was assessed at the 9-month visit
(visit 2), which was pre-specified for ACEi/ARB and beta-blockers,
and included the occurrence of hypotension (systolic blood
pressure < 90 mmHg, hyperkalemia (potassium concentration of >5.0
and > 5.5 mmoL/L of potassium), renal impairment [estimated glomer-
ular filtration rate (eGFR, as calculated by the Chronic Kidney Disease
Epidemiology Collaboration formula16) <30 ml/min/1.73m2] and bra-
dycardia (heart rate < 50 bpm).
We also considered “high-risk” subgroups as previously reported,17-22
as patient subpopulations that are more likely to experience adverse
events. These subgroups included: those with an age ≥ 75 years, a body
mass index (BMI) ≤25 kg/m2, a systolic blood pressure (SBP) ≤120 mmHg,
a heart rate ≤ 70 bpm, diabetes, New York Heart Association
(NYHA) class of III or IV, a LVEF ≤30%, Kansas City Cardiomyopa-
thy Questionnaire score (KCCQ score) ≤ median (60), and an eGFR
≤60 mL/min/1.73m2.
2.3 | Statistical analysis
Categorical variables are described as frequencies (percentages) and
continuous variables are described as means ± standard deviation or
median (25% and 75%), depending on their distribution. Comparisons
of demographic, clinical and biological parameters among patients for
whom reason was not reported, those experiencing symptoms/side
effects and those reaching target doses were conducted using χ2 tests
for categorical variables and ANOVA or Kruskal-Wallis test for contin-
uous variables.
Propensity score methods (i.e., matching, inverse probability
weighting and propensity score adjustment) has been reported to be
not necessarily superior to covariate adjustment.23 We thus report
results of covariate adjustment as the primary analysis. Considering
patients treated with target doses to be a reference group, clinical
determinants of those on suboptimal doses for unspecified reason or
those due to symptoms/side effects were selected in multinomial
logistic regression analysis with backward selection. All available
covariates with a small proportion of missing values (<10%) were
included in the models for ACEi/ARB and beta-blockers, and no multi-
ple imputation was performed. Potential confounders selected herein











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































KOBAYASHI ET AL. 3
were adjusted to compare incidences of adverse events associated
with ACEi/ARB and beta-blocker among patients for whom reason
was not reported, those experiencing symptoms/side effects, and
those reaching target doses.
All analyses were performed using R (R Development Core Team,
Vienna, Austria). p value< .05 was considered statistically significant.
3 | RESULTS
3.1 | Baseline characteristics
Among a total of 2100 patients included in the present study, 75.7%
were male, the mean age was 68.0 ± 12.0 years, the mean LVEF was
28.6 ± 7.5% and the mean eGFR was 61.7 ± 24.1 ml/min/1.73m2.
The baseline characteristics of patients in whom (a) no reason
was reported for not up-titrating ACEi/ARB or beta-blockers versus
(b) those experiencing symptoms/side effects versus (c) those
reaching target doses are shown in the Table 1 and Figure 1. For
ACEi/ARB, the distribution according to the aforementioned catego-
ries was: (a) 51.3% (N = 1061), (b) 25.9% (N = 536) and (c) 22.7%
(N = 470). Patients reaching target doses had higher BMI, less fre-
quent ischemic heart disease, less prior HF hospitalization, less con-
gestive signs, and symptoms, higher LVEF, SBP and better renal
function (all p values< .05).
For beta-blockers the distribution was: (a) 67.5% (N = 1405), (b)
20.2% (N = 420) and (c) 12.3% (N = 257). Patients reaching target
doses had more frequent atrial fibrillation, and higher heart rate (all p
values< .05).
Detailed information about no up-titration of ACEi/ARB or
beta-blockers due to symptom, side effects or non-cardiac organ
dysfunction is shown in Supplementary Table 1.
3.2 | Association of baseline characteristics with
patients not reaching target doses for unspecified
reasons or those not reaching target doses due to
symptoms/side effects
In multinomial logistic regression model for ACEi/ARB, lower BMI,
ischemic heart disease, more severe congestion, lower SBP and
poorer renal function were associated with less frequent up-titration
to target doses (in both groups (a) and (b)) that is, without and with
reason provided); whereas those from Northern European centers
and those with diabetes were more likely to reach target doses. In
addition, older age and lower ejection fraction were associated with
less frequent up-titration in the group without specified reason (all p
values< .05). Table 2.
Regarding beta-blockers with successful up-titration as the refer-
ence group, patients from Central European centers, those with more
severe congestion and those with lower heart rate were less likely to
be up-titrated to target doses (in both groups a) and b) that is, without



























































































































































































































































































































































































































































































































































































































































4 KOBAYASHI ET AL.
3.3 | Adverse events of up-titrating ACEi/ARB or
beta-blockers
At 9 months, hypotension, hyperkalemia (>5.0 and 5.5 mmoL/L) and
renal impairment occurred in 3.8%, 14.9%, 4.3% and 8.9% of patients,
respectively. For ACEi/ARB, after adjustment for potential con-
founders, hypotension, hyperkalemia and renal impairment occurred
at similar rates among 3 up-titration groups of patients (all adjusted p
values > 0.10). Table 3. In patients with an age ≥ 75 years, female sex,
a BMI≤25 kg/m2, a LVEF≤30% or an eGFR≤60 ml/min/1.73m2, there
was no between-group difference in adverse events (adjusted p
values > 0.10 for all subgroups) (Supplementary Table 2).
For beta-blockers, bradycardia and hypotension occurred in 1.5%
and 3.8% of patients, respectively. After adjustment for potential con-
founders, bradycardia and hypotension occurred at similar rates among
the three groups of patients (all adjusted p values > 0.10). Table 3. In
patients with an age ≥ 75 years, a BMI≤25 kg/m2, a heart
rate ≤ 70 bpm, NYHA of III/IV and impaired quality of life assessed by
KCCQ score, there was no between-group difference in the studied
adverse effects (adjusted p values > .05 for all subgroups) (Supplemen-
tary Table 3).
During the following stabilization period for ACEi/ARB, 7.2%
(N = 76) and 0.9% (N = 5) of patients in group (a) and (b) were success-
fully up-titrated, respectively, whereas 9.8% (N = 46) of patients in
group (c) did not maintain their target doses until 9 months. A sensi-
tivity analysis excluding these patients showed similar incidence of
adverse events among three groups (Supplementary Table 4). Simi-
larly, for beta-blockers, we excluded 5.6% (N = 78), 1.2% (N = 5) and
16.0% (N = 41) of patients in group (a), (b) and (c), and observed similar
rates of adverse events among three groups (Supplementary Table 4).
4 | DISCUSSION
In this prospective study of treatment optimization including a large
number of patients with symptomatic HFrEF on suboptimal therapy,
we show that patients in whom no reason was reported for not
reaching target doses of ACEi/ARB and/or beta-blockers had a similar
risk profile to those not up-titrated due to side effects. On the other
hand, patients reaching target doses had generally better clinical
status.
4.1 | ACE-inhibitor or ARB up-titration
In the present analysis, and consistently with prior reports, patients
with ischemic heart disease, those with more severe congestion, those
with lower SBP and those with poorer renal function were less likely
to initiate or reach target doses of ACEi/ARB.8,18,24-27 Older age and
lower EF were associated with poorer up-titration only in the group
of patients for whom no reason for no up-titration tentative was pro-
vided. These findings may be due to the general perception of higher
F IGURE 1 Main clinical characteristics. Non-cardiovascular comorbidities were defined as any of the following: diabetes mellitus, thyroid
dysfunction, anemia, chronic kidney disease (estimated glomerular filtration rate < 60 ml/min/1.73m2), chronic obstructive pulmonary disease,
current smoking and current cancer. ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index;
CV, cardiovascular; LVEF, left ventricular ejection fraction; IHD, ischemic heart disease; SBP, systolic blood pressure; eGFR, estimated glomerular
filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide
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rate of adverse effects related to advanced disease, comorbidity
burden, frailty or polypharmacy/risk of drug–drug interactions in
elderly patients,18,20,28,29 and suggest that clinicians introduce priors
in their decisions which is consistent with the Bayes' theorem that
integrates previous knowledge related to the conditions that may
influence an event or intervention. The introduction of priors in human
TABLE 2 Multinomial logistic regression model for patients not reaching target doses for unspecified reasons or those not reaching target
doses due to symptoms and/or side-effects
ACEi/ARB model
Unspecified reasons Symptoms or side effects
OR (95% CI) p value OR (95% CI) p value
European geographical area
Central countries (reference) (reference)
North countries 0.34 (0.25–0.48) <.0001 0.62 (0.43–0.91) 0.015
South countries 1.12 (0.83–1.53) 0.46 1.44 (1.01–2.05) 0.045
Age ≥ 75 years 1.39 (1.03–1.87) .029 1.04 (0.74–1.45) 0.82
Body mass index ≤25 kg/m2 1.41 (1.06–1.88) .019 1.68 (1.22–2.31) 0.002
Hypertension 0.60 (0.44–0.80) .0006 0.59 (0.43–0.83) 0.002
Diabetes 0.71 (0.54–0.94) .015 0.60 (0.43–0.82) 0.001
Ischemic heart disease 1.32 (1.01–1.73) .04 1.53 (1.13–2.08) 0.006
LVEF ≤30% 1.52 (1.17–1.98) .002 1.18 (0.87–1.60) 0.28
Orthopnea 1.71 (1.29–2.27) .0002 1.49 (1.08–2.06) 0.015
Systolic BP ≤110 mmHg 2.64 (1.91–3.65) <.0001 2.76 (1.94–3.94) <0.0001
eGFR <45 ml/min/1.73m2 1.70 (1.19–2.42) .003 3.05 (2.10–4.43) <0.0001
Unspecified reasons Symptoms or side effects
Beta-blocker model OR (95% CI) p value OR (95% CI) p value
European geographical area
Central countries (reference) (reference)
North countries 0.22 (0.15–0.32) <.0001 0.38 (0.25–0.58) <.0001
South countries 0.57 (0.39–0.84) .004 0.63 (0.41–0.98) .039
Hypertension 0.67 (0.50–0.89) .006 0.86 (0.61–1.20) 0.36
Orthopnea 1.54 (1.13–2.10) .006 2.01 (1.42–2.84) < .0001
Heart rate ≤ 70 bpm 1.40 (1.04–1.89) .027 1.84 (1.31–2.58) .0004
Note: Patients who reached target doses are considered a reference group.
Bold values if p-value < 0.05.
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; eGFR, estimated glomerular
filtration ratio; LVEF, left ventricular ejection fraction; OR, odd ratio.
TABLE 3 Comparison of adverse events associated with ACEi/ARB or beta-blockers among patients not reaching target doses for
unspecified reason, those not reaching target doses due to symptoms/side effects, and those reaching target doses
ACEi/ARB Unspecified reasons Symptoms or side effects Target doses Adjusted p value
Hypotension, N (%)(SBP < 90 mmHg) 31 (3.5%) 27 (6.5%) 7 (1.7%) 0.31
Renal impairment, N (%)(eGFR<30 ml/min/1.73m2) 54 (8.5%) 40 (13.4%) 17 (5.4%) 0.11
Hyperkalemia, N (%)(Potassium>5.0 mmoL/L) 102 (16.6%) 40 (13.7%) 39 (12.8%) 0.64
Hyperkalemia, N (%)(Potassium>5.5 mmoL/L) 23 (3.7%) 19 (6.5%) 10 (3.3%) 0.22
Beta-blockers Unspecified reasons Symptoms or side effects Target doses Adjusted p value
Hypotension, N (%)(SBP < 90 mmHg) 48 (4.2%) 11 (3.3%) 6 (2.7%) 0.51
Bradycardia, N (%)(Heart rate < 50 bpm) 18 (1.6%) 3 (0.9%) 3 (1.3%) 0.48
Note: Comparisons among three groups were adjusted for covariates which were selected in multinomial logistic regression analyses for ACEi/ARB or
beta-blocker, respectively.
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure; eGFR, estimated
glomerular filtration rate.
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decisions has been seminally described elsewhere,30 and suggests that
our experience may serve as an anchor on which we hold for decision
making. In other words, applying to the current example, elderly
patients with more comorbid conditions experience more side-effects
from treatments, especially at higher doses, and this is observed in
daily practice and confirmed by data; hence, many clinicians may assume
that all elderly/sick HF patients will experience side-effects and, there-
fore, do not deserve to be up-titrated. However, this clinical inertia may
not hold in all cases, as we observed that patients with successful up-
titration of ACEi/ARB had similar rates of hypotension, hyperkalemia
and renal impairment to those previously reported in clinical trials.2,3,31 In
a report of the Effects of High-dose versus Low-dose Losartan on Clini-
cal Outcomes in patients with Heart Failure (HEAAL) trial (N = 3846),
patients assigned with the high-dose losartan had low rates of side
effects, but, numerically, these side effects were slightly higher compared
with those with the low-dose losartan.2,32,33 In the Comparative Effects
of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor,
Lisinopril, on Morbidity and Mortality in Chronic Heart Failure (ATLAS)
trial (N = 3164), comparing between high- and low-dose groups, rela-
tively small difference in mean SBP (<5 mmHg) and similar incidence rate
of major increases in creatinine (>1 mg/dl) were observed.3 A report of
the Clinical Outcome with Enalapril in symptomatic chronic Heart Failure:
a dose comparison (NETWORK) trial (N = 1532) comparing high-,
medium- and low-dose of enalapril showed similar rates of renal impair-
ment and hyperkalemia across three dose strata.31 Importantly, it should
be noted that there was no dose-dependent difference in incidence rate
of adverse events leading to drug discontinuation in these clinical trials.
Generally, certain subgroups, such as the elderly, those with impaired
renal function, those with low BMI and/or diabetes are reported to be at
higher risk of adverse effects associated with ACEi/ARB,18,34 and among
subgroups with these high-risk profiles, higher doses of ACEi/ARB may
increase a risk of adverse effects.35,36 However, in the present study, we
found similar proportion of adverse events between older patients who
reached target doses and those who did not, suggesting that this high-
risk subgroup should generally be treated with guideline-directed medical
therapy. Body size may be also the dominant reason for prescribing lower
doses. A recent registry data showed that patients with a lower BMI
were less likely to be up-titrated.37 However, incidence of adverse events
did not differ across BMI categories in the present analysis. In addition,
we observed similar adverse events in patients with low blood pressure
and/or those with poor renal function. Importantly, treatment up-titration
may thrive higher absolute net benefit in these high-risk subgroups.38-40
4.2 | Beta-blocker up-titration
Only about 10% of patients reached target doses of beta-blockers.
Regardless of reason for not up-titrating, and consistently with previous
findings, patients who had lower heart rate and those with more severe
congestion were less likely to be up-titrated to target doses.8,22,41 As for
ACEi/ARBs, this finding may be explained by clinicians' prior concern
about the safety of beta-blockers in patients with lower heart rate and
congestion. As for ACEi/ARBs, in the present analysis, we observed low
rates of adverse events (e.g., bradycardia and hypotension) associated
with the prospective up-titration of beta-blockers.4,5 In the Carvedilol
produces Dose-related Improvements in Left Ventricular Function and
Survival in subjects with chronic Heart Failure (MOCHA) trial comparing
high-, medium-, and low-dose carvedilol in 345 patients with chronic HF,
higher doses of carvedilol were associated with higher incidence of bra-
dycardia, but without compromising the benefit of high-dose carvedilol.4
It should be noted, however, that in MOCHA, the majority of patients
(>90%) received digitalis, which may increase dose-dependent incidence
rate of bradycardia in combination with beta-blockers.42 A more recent
report showed no association between beta-blocker dose and bradycar-
dia, which is in line with our findings.5 Also, data from large-scale regis-
tries showed that older age, lower heart rate, decreased quality of life
and/or female sex were associated with increased risk of adverse
events.8,22 However, in our report, there was no significant difference in
rate of adverse events in each high-risk subgroup, irrespective of the rea-
son of not up-titrating to target doses. These findings suggest again that
physicians may be concerned about the likelihood of drug intolerance in
high-risk HF patients, consequently triggering therapeutic inertia.
4.3 | Clinical implications
Several reports suggest that heart failure medications are under-
prescribed and often not optimally up-titrated, especially in subgroups
with high risk of adverse events, such as the elderly, those with multiple
concomitant treatments, high comorbidity burden, low blood pressure or
impaired renal function.13,19,38-40,43,44 In addition, recent registry data
showed that in approximately 20% of patients, provider-related issues
such as provider inertia and aversion were underlying reason for dose
decrease or discontinuation of ACE inhibitor/ARB or beta-blockers.8
Our data show that sub-optimal HF therapy up-titration is not solely
related to objective clinical presentations (e.g., low blood pressure, hyper-
kalemia, or poor renal function). Many clinicians may have their decisions
influenced by a prior belief that, in high-risk patients, side-effects will
occur in the short-term which may be perceived as more important than
the potential long-term benefits. However, from these observational
findings, one cannot determine if the adverse event pattern among these
patients would be better or worse than that of patients not up-titrating
due to objective reasons. Behavioral interventions, including formal train-
ing in risk management and decision-making, and established algorithm
might mitigate physician inertia and risk aversion.45-47
5 | LIMITATIONS
Although BIOSTAT-CHF prospectively enrolled HFrEF patients
who had no optimal doses of HF medications, with the aim of ther-
apy optimization, our study has several limitations. This study relies
on a post-hoc analysis, hence the causality cannot be inferred. The
BIOSTAT-CHF study was designed to address ACEi/ARB and
beta-blocker up-titration, thus these data may not be suitable for
accounting for mineralocorticoid receptor antagonist prescription
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or treatment dose. Although we tried to eliminate bias as much as
possible using covariate adjustment, unmeasured potential con-
founders may remain. No up-titration for unclear reason may be
likely due to the short titration period, patient or physician compli-
ance to the guidelines-based recommendation. Although investiga-
tors were instructed to record all reasons for dose change per the
protocol of BIOSTAT-CHF, further specific reasons for not reaching
target doses was lacking. Furthermore, types of health care pro-
viders (i.e., general practitioners or cardiologists) may influence our
findings. We also may have not been able to exclude an attribution
bias, that is, lower-risk patients may receive higher doses of HF
medications, and these patients are also less likely to experience
adverse effects. We tried to study the high-risk subgroups, but an
attribution bias cannot be eliminated. Lastly, we had no available
clinical follow-up data at the end of the up-titration period. However,
a sensitivity analysis excluding patients who were changed their treat-
ment doses during the stabilization period did not alter the interpretation
of our results.
6 | CONCLUSIONS
Patients in whom clinicians did not give a reason why up-titration was
missed were older and had more co-morbidities. Patients in whom up-
titration was achieved did not have excess adverse events. However,
from these observational findings, the pattern of subsequent adverse
events among patients in whom up-titration was missed cannot be
determined.
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